The Synairgen share price has rocketed 500% in two days! Here’s what I’d do now

The Synairgen share price (LON:SNG) has had a storming two days following positive results on a potential treatment for coronavirus. Should new investors go all-in?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Yesterday, respiratory drug developer Synairgen (LSE: SNG) jumped an astonishing 420% in value. It’s up another 15% this morning. Could there be even more to come? Quite possibly. That said, I think anyone investing should keep their expectations in check.

Before explaining why, let’s have a recap.

What’s behind Synairgen’s rise?

Monday’s share price jump followed news of a successful trial of a treatment. labelled SNG001 (an inhaled dosage of interferon beta), in patients who had been hospitalised as a result of coronavirus.

Results showed those who received the drug in a double-blind trial (where neither the patient nor the clinician knows who is getting what) had a 79% lower risk of severe disease compared to those who received the placebo. Those on SNG001 were also more than twice as likely to recover than those who didn’t receive the drug.  

With concerns that the arrival of winter could bring about a fresh wave of the coronavirus, news that the treatment helps the lungs to tackle the virus, even in the event of co-infection (e.g. if a person catches flu), is clearly very positive. 

Can the share price keep rising?

Here, from an investment point of view, is where things get tricky.

What’s important to remember — and the company clarified today — is that the recent positive outcome was a Phase 2 trial. This phase is “designed to test the efficacy of a drug and takes place before the drug is approved or able to be marketed.” In other words, a lot of questions still need answering.

While positive that patients in both groups were matched with each other in things like age, this trial involved just 101 patients — a very small sample. Also, all were recruited in the UK, which means results might not be generalisable to other countries.

Nor did every finding from the trial reach statistical significance. In other words, we can’t be absolutely sure that what was found wasn’t just down to luck. Naturally, all this makes a much larger trial of the treatment (Phase 3 of drug development) absolutely essential. 

In short, I think SNG001 is still far from the sure thing the market presumably now believes it to be. For me, this has implications for what the Synairgen share price will do next.

The problem is that not everyone will want to stick around for the ride. It will, after all, be a few weeks before the company is ready to reveal the outcome of further analyses. If I were a trader and knew this, I’d seriously consider banking some profit on Synairgen.

And if I were a Foolish investor buying stocks for the long term (and I am), I’d be sure to appreciate that some in the market work on much shorter timescales and act (or not act) accordingly.

Buyer beware

Synairgen could certainly still reward those buying in now. However, I would caution anyone against thinking they can make easy money in a set period of time. It’s very easy to find examples of promising treatments that failed to live up to the initial hype and progress beyond Phase 3.

We must not allow our desire for a quick profit to override our true tolerance for risk. If you’re going to expect anything from the share price, expect volatility. Don’t bet the ranch and ensure you’re diversified elsewhere.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Paul Summers has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

The Rolls-Royce share price hit new highs in November. What next?

November has been another record-breaking month for the Rolls-Royce share price. And the outlook for 2025 still looks bright.

Read more »

Investing Articles

Here’s the growth forecast for Sage Group shares to 2026!

Sage Group shares have rocketed following the tech firm's stunning third-quarter update. Is now the time to consider buying in?

Read more »

Investing Articles

10%+ dividend growth! 2 FTSE 250 shares tipped to turbocharge dividends

These FTSE 250 income shares look in great shape to grow their dividends by double-digit percentages, says our writer Royston…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Investing Articles

Would it be madness to buy this FTSE stock smashed by Donald Trump’s team picks?

Ben McPoland takes a look at one FTSE share inside his portfolio that has been battered lately due to a…

Read more »

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »